A new report has been released by Abbvie announcing an FDA approval of Humira for treatment of pediatric Crohn’s disease. Humira has become the only biological drug to get the FDA approval for this indication. It is estimated that 38,000 pediatric patients are suffering form Crohn’s disease only in the United States. Humira is a self-administered tumor necrosis factor – alpha (TNF-a) inhibitor, and it was already approved in Europe as an alternative treatment of Crohn’s disease. Based on your experience, how would this approval change the pediatric clinical practice related to Crohn’s disease?
For more information, please see IBD News Today.
Image courtesy of [m_bartosch] / FreeDigitalPhotos.net